BLFS
BioLife Solutions, Inc. · Healthcare
Insiders sold $31.3M of BioLife Solutions, Inc. in the last 12 months and bought none
BLFS over the last year
BLFS after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
339 insider filings since 2018, newest first
Casdin Partners Master Fund, L.P. · 10% owner
Karen A. Foster · Chief Quality, Operations
Karen A. Foster · Chief Quality, Operations
Troy Wichterman · CFO
Troy Wichterman · CFO
Amy Duross · Director
Troy Wichterman · CFO
Amy Duross · Director
Amy Duross · Director
Aby J. Mathew · EVP and Chief Scientific Officer
Aby J. Mathew · EVP and Chief Scientific Officer
Aby J. Mathew · EVP and Chief Scientific Officer
Troy Wichterman · CFO
Garrie Richardson · Chief Revenue Officer
Sarah Aebersold · CHRO
Todd Berard · CMO
Todd Berard · CMO
Todd Berard · CMO
Sarah Aebersold · CHRO
Amy Duross · Director
Todd Berard · CMO
Aby J. Mathew · EVP and Chief Scientific Officer
Troy Wichterman · CFO
Geraint Phillips · SVP, Global Operations
Greef Roderick De · President and CEO
Karen A. Foster · Chief Quality, Operations
Sarah Aebersold · CHRO
Troy Wichterman · CFO
Geraint Phillips · SVP, Global Operations
Greef Roderick De · President and CEO
Michael Rice · Former CEO and Director
Casdin Partners Master Fund, L.P. · 10% owner
Aby J. Mathew · EVP and Chief Scientific Officer
Aby J. Mathew · EVP and Chief Scientific Officer
Michael Rice · CEO
Aby J. Mathew · EVP and Chief Scientific Officer
Casdin Partners Master Fund, L.P. · 10% owner
Michael Rice · CEO
Aby J. Mathew · EVP and Chief Scientific Officer
Todd Berard · CMO
Michael Rice · CEO
Aby J. Mathew · EVP and Chief Scientific Officer
Aby J. Mathew · EVP and Chief Scientific Officer
Troy Wichterman · CFO
Aby J. Mathew · EVP and Chief Scientific Officer
Troy Wichterman · CFO
Karen A. Foster · Chief Quality Officer
Michael Rice · CEO
Todd Berard · CMO
Aby J. Mathew · EVP and Chief Scientific Officer
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.